Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
Pedro C BarataJorge A Garcia

Abstract

We assessed the clinical outcomes of patients with oligoprogressive renal cell carcinoma (mRCC) treated with stereotactic radiosurgery (SRS), stratified by changing or continuing systemic treatment. Ninety-five consecutive patients with clear cell mRCC who had undergone SRS to the central nervous system (CNS) or spine during systemic treatment were divided into 3 cohorts: those who continued the same systemic therapy (STAY), those who changed systemic treatment after SRS (SWITCH), and patients with progression outside the SRS sites, who also changed systemic treatment (PD-SYS). The primary outcome was treatment duration after SRS, defined as the interval between SRS and discontinuation of the current systemic therapy for the STAY group and discontinuation of the first subsequent therapy in the SWITCH and PD-SYS groups. Local control with SRS was achieved in 85% of the patients. The most common systemic treatment at SRS included anti-vascular endothelial growth factor (67%), mammalian target of rapamycin (14%), and programmed cell death protein 1 inhibitors (9%). The median treatment duration for the STAY group was 5.2 months (95% confidence interval [CI], 3.5-6.9) compared with 5.0 months (95% CI, 4.3-5.7) for the SWITCH group ...Continue Reading

Citations

Apr 3, 2020·American Society of Clinical Oncology Educational Book·Matthew TenoldPrimo N Lara
Jun 2, 2020·Expert Review of Anticancer Therapy·Maddalena DoniniMatteo Santoni
Jan 14, 2021·Current Treatment Options in Oncology·Bryce R ChristensenPedro C Barata
Jan 15, 2020·Deutsches Ärzteblatt International·Jan HaussmannWilfried Budach
Apr 2, 2021·American Society of Clinical Oncology Educational Book·Andrew L SchmidtRana R McKay
Oct 9, 2019·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·M WespiserA Thiery-Vuillemin
Apr 27, 2021·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Aditya Juloori, Everett E Vokes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.